Still on the Rebound, Invitrogen Q2 Revs Increase 13 Percent, BioDiscovery Steady | GenomeWeb
Continuing on the road back from a rocky 2006, Invitrogen this week reported a 12.7 percent jump in second-quarter revenues, helping profits increase 107 percent.
Revenues company-wide for the three months ended June 30 reached $321.7 million, up from $285.4 million a year ago. For Invitrogen’s BioDiscovery division, which houses its proteomics tools among other product lines, revenues rose 9.9 percent to $222.8 million from $202.8 million during the year-ago period.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.